Program
azetukalner
Also written as “XEN1101”, “Azetukalner” and “XEN1101 10 mg”.
Its studies are mostly in Depressive Disorder, Major · Epilepsies, Partial · Seizures · Bipolar Disorder · Epilepsy, led by Xenon Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Xenon Pharmaceuticals | 129 open or running | phase 3since Nov 6, 2022 | Jan 2, 2019 | Jan 2027phase 3 · NCT06922110 |
Also a collaborator on its studies: novotech-health-holdings-pte-ltd.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 2, 2019First study: phase 2 study in Epilepsies, PartialFirst studyNCT03796962 · 325 enrolled · United States, Canada, Georgia and more
- Jun 27, 2021Phase 1 study in Healthy VolunteersNCT04952467 · 6 enrolled · United Kingdom
- May 11, 2022Phase 2 study in Depressive Disorder, MajorNCT05376150 · 168 enrolled · United States
- Nov 6, 2022Phase 3 study in SeizuresNCT05614063 · 380 enrolled · United States, Argentina, Australia and more
- Dec 19, 2022Phase 3 study in EpilepsyNCT05667142 · 160 planned · United States, Argentina, Australia and more
- Jan 13, 20232 phase 3 studiesNCT05718817, NCT05716100
- Jan 9, 2025Phase 3 study in Depressive Disorder, MajorNCT06775379 · 450 enrolled · United States
- Mar 20, 2025Phase 3 study in Depressive Disorder, MajorNCT06922110 · 460 enrolled · United States, Finland, Poland
- Jul 14, 2025Phase 3 study in Depressive Disorder, MajorNCT07076407 · 450 enrolled · United States, Finland, Germany and more
- Sep 8, 2025Phase 3 study in Bipolar DisorderNCT07172516 · 400 enrolled · United States, Bulgaria, Germany and more
- Oct 14, 2025Phase 3 study in Bipolar DisorderNCT07217860 · 400 enrolled · United States
- Oct 8, 2026Primary completion moved from 2026-10 to 2028-01Date moved laterphase 3 · +15 months · NCT05716100
- Oct 13, 2026Primary completion moved from 2026-08 to 2026-10Date moved laterphase 3 · +2 months · NCT06775379
Ahead
- Jan 2027Primary completion: phase 3 study in Depressive Disorder, MajorNCT06922110
- Apr 2027Primary completion: phase 3 study in EpilepsyNCT05667142
- May 2027Primary completion: phase 3 study in Depressive Disorder, MajorNCT07076407
- Jan 2028Primary completion: phase 3 study in SeizuresNCT05716100
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07217860Bipolar Disorder · United States | 3 | Active, not recruiting | Jun 2029 | 400 |
| NCT07172516Bipolar Disorder · United States, Bulgaria, Germany and more | 3 | Active, not recruiting | Jun 2028 | 400 |
| NCT07076407Depressive Disorder, Major · United States, Finland, Germany and more | 3 | Active, not recruiting | May 2027 | 450 |
| NCT06922110Depressive Disorder, Major · United States, Finland, Poland | 3 | Active, not recruiting | Jan 2027 | 460 |
| NCT06775379Depressive Disorder, Major · United States | 3 | Active, not recruiting | Oct 2026 | 450 |
| NCT05716100Seizures · United States, Argentina, Australia and more | 3 | Recruiting | Jan 2028 | 360 |
| NCT05718817Epilepsies, Partial · United States, Argentina, Australia and more | 3 | By invitation | Apr 2033 | 880 |
| NCT05667142Epilepsy · United States, Argentina, Australia and more | 3 | Recruiting | Apr 2027 | 160 |
| NCT05614063Seizures · United States, Argentina, Australia and more | 3 | Completed | Jan 12, 2026 | 380 |
| NCT05376150Depressive Disorder, Major · United States | 2 | Completed | Sep 18, 2023 | 168 |
| NCT04952467Healthy Volunteers · United Kingdom | 1 | Completed | Oct 4, 2021 | 6 |
| NCT03796962Epilepsies, Partial · United States, Canada, Georgia and more | 2 | Active, not recruiting | Sep 2, 2021 | 325 |
How it is read
Names in the registry
- “XEN1101”, 5 entries
- “Azetukalner”, 5 entries
- “XEN1101 10 mg”, 1 entry
- “XEN1101 20 mg”, 1 entry
- “14C-XEN1101”, 1 entry
Conditions, from the studies’ own filings
- Depressive Disorder, Major, 4 studies
- Epilepsies, Partial, 2 studies
- Seizures, 2 studies
- Bipolar Disorder, 2 studies
- Epilepsy, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.